Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

Table 1 Baseline and Treatment Information for The Analytical Cohort of MCL Cases (n = 586)

Parameter	Quantity	n	%	Parameter	Quantity	n	%
Age ≥ 65y	354	578	61.2	Lymphocytes (> 5˟10³/μL)	93	457	20.4
Male	455	581	78.3	Anemia	176	508	34.7
Caucasian	452	507	89.2	Platelets (≤ 100 k/μL)	78	510	15.3
ECOG Performance < 2	502	538	93.3	Circulating tumor cells	134	345	38.8
B symptoms presented	131	538	24.3	Largest tumor diameter (≥ 3 cm)	230	444	51.8
Nodal involvement only	151	550	27.5	Blastoid or Pleomorphic	38	222	17.1
Extranodal involvement				Diffuse growth pattern	91	223	40.8
Tonsil	37	395	9.4	CD5 positive	252	279	90.3
Colon	72	490	14.7	CD23 positive	25	186	13.4
Liver	22	490	4.5	Kappa light chain restriction	59	139	42.4
Small intestine	50	490	10.2	p53 (≥ 0.9 points)	77	273	28.2
Spleen	134	490	27.3	Ki-67 (≥ 30%)	100	306	32.7
Stomach	24	490	4.9	SOX11 (≥ 10%)	181	202	89.6
Digestive tract	98	490	20.0	Chemotherapy regimens
Limited to one site	29	527	5.5	Cytarabine-based	159	503	31.6
AAS III-IV	488	548	89.1	Anthracycline-based	244	503	48.5
Elevated LDH	179	453	39.5	Purine analogue-based	69	503	13.7
Elevated Beta-MG	93	159	58.5	Others	31	503	6.2
Clonal Ig	23	105	21.9	Rituximab maintenance	96	485	19.8
WBCs (> 11˟10³/μL)	116	523	22.0	HSCT	167	511	32.7
Neutrophils (> 10˟10³/μL)	7	455	1.5	Auto-SCT vs Allo-SCT	133/33	166	80.1/19.9

AAS Ann Arbor stage, Beta-MG beta-microglobulin; LDH lactate dehydrogenase; SCT stem cell transplantation; and WBC white blood cell

ISSN: 1756-8722